Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

BTG and the New England Medical Center sign marketing agreement

Aug. 23, 1996

Santen reveals neutral endopeptidase inhibitors

Aug. 23, 1996

BMS-186716: Bristol-Myers Squibb's ACE/neutral endopeptidase inhibitor

Aug. 23, 1996

Carvedilol approved for CHF indication in Spanish market

Aug. 23, 1996

Adenosine reuptake inhibitors from Kyowa Hakko

Aug. 23, 1996

Thiazolidinone compounds as antianginal agents from Sankyo

Aug. 23, 1996

Roche reveals EGF-R tyrosine kinase inhibitors

Aug. 23, 1996

Phospholipase A2 inhibitors from SmithKline Beecham

Aug. 23, 1996

European patent protection issued for Hyal's hyaluronan technology

Aug. 23, 1996

Apolipoprotein A-IV as atherosclerosis treatment

Aug. 23, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...